NewcelX AG Announces Ordinary Shareholders' Meeting for June 30, 2026
NewcelX AG has issued a notice for its ordinary shareholders' meeting scheduled for June 30, 2026, in Zurich. The agenda includes several key items such as the re-election of the independent proxy and auditor, approval of the 2025 statutory financial statements, and an advisory vote on the 2025 compensation report. Shareholders will also vote on the appropriation of the balance sheet results for 2025, which indicates a significant net loss. Additionally, proposals cover the discharge of the Board of Directors and Executive Management, re-election of Board members and the Compensation, Nomination and Governance Committee, and approval of compensation amounts for the Board and Executive Management. The meeting will also address ordinary capital increases through six tranches, each up to CHF 50,000, with subscription rights excluded, and proposed amendments to the company's Articles of Association concerning the capital band and conditional share capital.
Key Highlights
- NewcelX AG announces its ordinary shareholders' meeting on June 30, 2026, in Zurich.
- Agenda includes re-election of independent proxy, approval of 2025 financial statements, and advisory vote on 2025 compensation report.
- Shareholders will vote on appropriation of balance sheet results for 2025, showing a net loss of CHF -38,642,417.
- Proposals also cover discharge of Board and Executive Management, re-election of Board members and Compensation Committee, and re-election of Auditor.
- Approval sought for aggregate fixed and equity compensation for Board and Executive Management for upcoming terms/years.
- Plan to increase share capital by up to CHF 50,000 per tranche across six tranches (A-F), with exclusion of subscription rights.
- Proposed amendments to Articles of Association regarding capital band and conditional share capital for shareholders' options.
Price Impact
More from NCEL